POSCO BioVentures' primary investment focus is on companies with novel,
proprietary bio-molecules. POSCO BioVentures expects that 70%
of its investments will be in companies focused on novel proprietary
bio-molecules, with the balance of the investments in other enabling
technologies.
POSCO BioVentures will invest in companies in different stages
of development. Early stage companies will comprise approximately
one-third of our investments. Late stage opportunities, which we
anticipate will be about one quarter of our investments, are those deals
where an exit strategy is expected as the next round of funding, and in
a relatively short period of time. We will also consider mid stage
investments with clear milestones toward an exit defined.
